University Hospital Kralovske Vinohrady
Welcome,         Profile    Billing    Logout  
 5 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cerna, Olga
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Active, not recruiting
3
117
Europe, RoW
Ropeginterferon alfa-2b (BESREMi®)
AOP Orphan Pharmaceuticals AG
Essential Thrombocythaemia
03/28
03/28
KER050-MD-201, NCT04419649 / 2021-001838-19: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Hourglass Dec 2024 - Dec 2024 : Additional data for very low, low, or intermediate risk myelodysplastic syndrome
Hourglass Jul 2023 - Dec 2023 : Enrollment completion of transfusion dependent cohorts of trial for low, or intermediate risk MDS
Recruiting
2
140
Europe, US, RoW
KER-050
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Myelodysplastic Syndromes, Cytopenia
06/25
11/25
Mocikova, Heidi
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
Duska, Frantisek
NCT06147674: Evaluation of VQm PHM on Pulmonary Health Parameters for ICU

Not yet recruiting
N/A
150
Europe, US, RoW
VQm Pulmonary Health Monitor™
Rostrum Medical Innovations Inc., Medical Initiatives
Ventilators, Mechanical, Stroke, COPD, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Pneumonia
01/25
03/25
Rob, Lukas
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
Curila, Karol
LEAP-pilot, NCT04595487: LVSP vs RVP in Patients With AV Conduction Disorders

Recruiting
N/A
470
Europe, RoW
Left ventricular septal pacing, Right ventricular pacing
Maastricht University, ZonMw: The Netherlands Organisation for Health Research and Development, Medtronic
Cardiac Pacing, Pacing-Induced Cardiomyopathy, Conduction System Pacing, Left Ventricular Septal Pacing, Atrioventricular Block
05/25
05/25

Download Options